Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

Less than a year after approval, Pfizer said it plans to discontinue its hemophilia B gene therapy fidanacogene elaparvovec ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for ...

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in ...

The hemophilia market is expected to experience significant growth due to advancements in gene therapy, innovative treatments, and an increasing focus on personalized medicine. Rising awareness and ...

Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.

Pfizer will focus on Hympavzi, the first U.S.-approved anti-TFPI for hemophilia. Beqvez was FDA-approved in April 2024 but saw low adoption from patients. Get real-time earnings alerts before the ...